logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

FOMO panic buying has triggered a surge in S&P bullish options, revealing a phenomenon of "one-way order flow" in the market.

date
06/08/2026
According to Zhihong Finance APP, traders' enthusiasm for betting on further increases in the S&P 500 index continues to risethis benchmark index, which has been overshadowed by the more volatile Nasdaq 100 index in recent months, is now regaining fervent support in the options market.
Latest
1 m ago
Yidun Electronics (603328.SH) plans to invest 2.979 billion yuan to construct an intelligent manufacturing project for high-end printed circuit boards.
3 m ago
After the U.S. Energy Information Administration announced that the increase in natural gas inventories met expectations, U.S. natural gas futures continued to decline, falling by 2.1%.
4 m ago
Yidun Electronics (603328.SH) plans to raise no more than 2 billion yuan through a private placement for a high-end printed circuit board intelligent manufacturing project.
4 m ago
US stock movement | Zai Ding Pharmaceutical (ZLAB.US) surged over 12% as Q2 product revenue increased by 11% quarter-on-quarter.
5 m ago
Yiteng Jiahe (06998): The first subject has been dosed in the Phase Ib/II clinical trial of GB268.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.